Quantcast

Latest cell therapy Stories

2014-09-10 16:24:07

Media Company Mary Ann Liebert, Inc., Makes Foray from Scientific & Medical Journals to Consumer Arena with Launch of New Non-Fiction Work Inevitable Collision NEW ROCHELLE, New York, Sept. 10, 2014 /PRNewswire/ -- Mary Ann Liebert, Inc., leading publisher of over 80 science, technology, and medical publications, announced today the launch of first time hard cover title Inevitable Collision: The Inspiring Story that Brought Stem Cell Research to Conservative America, in an effort to...

2014-09-08 23:05:50

Okyanos Heart Institute Now Accepting Qualified Heart Disease Candidates for Adult Stem Cell Treatment in New State-of-the-Art Cath Lab Freeport, Grand Bahama (PRWEB) September 08, 2014 Adult stem cell therapy for heart disease has emerged as a new treatment alternative for those living with a poor quality of life as a result of severe coronary artery disease. Okyanos is slated to begin delivering this innovative new treatment in the next several weeks, and is now screening qualified...

2014-09-05 08:24:18

Live Webcast on Wednesday, September 10, at 2:55 p.m. EST GERMANTOWN, Md., Sept. 5, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16(th) Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 10, at 2:55 p.m. EST. Garr will provide an overview of the company's NSI-566 cell therapy clinical trials for ALS, which concluded final Phase II treatments in July, and chronic spinal cord...

2014-09-04 16:27:31

MENLO PARK, Calif., Sept. 4, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY) announced today that its Board of Directors has set Monday, September 15, 2014 as the record date (the "Record Date") for determining holders of its Series A common stock entitled to receive BioTime, Inc. common share purchase warrants in Asterias' previously announced warrant distribution. Asterias plans to distribute, on a pro rata basis, warrants to purchase 8,000,000 BioTime common...

2014-08-29 23:10:02

For more than a week, Boston’s Adult Stem Cell Technology Center, LLC has been declining offers from participants in the Amyotrophic Lateral Sclerosis (ALS) Ice Bucket Challenge who wish to make donations for research that does not use human embryonic stem cells or tissues derived from aborted fetuses. The company has informed those wishing to donate that its for-profit status prevents it from inviting or receiving charitable donations. Boston, MA (PRWEB) August 29, 2014 Due to a...

2014-08-27 08:26:50

Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration MENLO PARK, Calif., Aug. 27, 2014 /PRNewswire/ -- Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. The approved trial follows the...

2014-08-25 08:27:03

- Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT - MENLO PARK, Calif., Aug. 25, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host an investor briefing conference call and slide presentation via webcast on Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. At this briefing, Asterias management will review the Company's business...

2014-08-22 23:05:03

Cryo-Cell International, Inc., the world’s first cord blood bank, announced today that it has provided funding to complete an Investigational New Drug Application (IND) for a FDA approved Phase I clinical trial for patients that have amyotrophic lateral sclerosis (ALS or Lou Gehrig's) disease using umbilical cord blood cells. Oldsmar, FL (PRWEB) August 22, 2014 This funding was made through an additional investment in Cryo-Cell’s cell therapy research affiliate, Saneron CCEL...

2014-08-21 08:29:07

SAN DIEGO, Aug. 21, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research & Development LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01(TM) combination product that ViaCyte is developing for type 1 diabetes. This right will continue...

2014-08-21 08:28:11

- Welcomes New Shareholders Who Received Series A Shares from Geron Corporation - MENLO PARK, Calif., Aug. 21, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy") Arno and Natale ("Nat") Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.